ESMO 2023 | CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the design of the on-going Phase III CAMBRIA-1 (NCT05774951) study. This trial aims to assess the efficacy of extended adjuvant therapy with the selective estrogen receptor degrader (SERD) camizestrant in patients with ER+/HER2- early breast cancer with an intermediate or high risk or recurrence after 2-5 years of definitive locoregional therapy and standard adjuvant endocrine therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.